INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.530
+0.170 (7.20%)
At close: Jul 3, 2025, 1:00 PM
2.550
+0.020 (0.79%)
After-hours: Jul 3, 2025, 4:53 PM EDT
INmune Bio Employees
As of December 31, 2024, INmune Bio had 22 total employees, including 13 full-time and 9 part-time employees. The number of employees increased by 5 or 29.41% compared to the previous year.
Employees
22
Change (1Y)
5
Growth (1Y)
29.41%
Revenue / Employee
$2,273
Profits / Employee
-$1,854,364
Market Cap
67.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INMB News
- 1 day ago - INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's - Seeking Alpha
- 1 day ago - 'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
- 5 days ago - INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 5 days ago - Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain - Benzinga
- 5 days ago - INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study - Reuters
- 5 days ago - INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease - GlobeNewsWire
- 8 days ago - INmune Bio: Finding Pay Dirt In Alzheimer's? - Seeking Alpha
- 8 days ago - INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire